Business Wire

NATIONAL-TSING-HUA-UNIV

4.3.2020 10:02:08 CET | Business Wire | Press release

Share
NTHU Research Team Teaches Drone to Fly Like an Insect

Although unmanned aerial vehicles (UAV) are commonly used in the fields such as communications and agriculture, their use is hampered by their small size and limited battery capacity. However, a multi-disciplinary team at National Tsing Hua University led by professors Tang Kea-tiong of the Department of Electrical Engineering and Lo Chung-chuan of the Department of Life Sciences has recently developed an artificial intelligence (AI) chip that mimics the optical nerves of the fruit fly, allowing drones to automatically avoid obstacles while remaining in an ultra-power-saving mode.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005029/en/

Most of the UAVs currently in use rely on the transmission and reflection of electromagnetic waves to detect and avoid obstacles, but this consumes a lot of power. An alternative approach to avoiding obstacles is to use optical lenses to capture and analyze images, but the amount of information to be processed is too large to be done quickly, and this approach also consumes much power.

Intrigued by the fruit fly’s uncanny ability to avoid obstacles, Tang figured that it might be possible to replicate the optical nerve of this tiny insect and adapt it to AI applications.

The first task was to solve the problem of information overload. According to Tang, the image sensor currently used in cameras and mobile phones have millions of pixels, whereas the eye of a fruit fly has only about 800 pixels. When the fruit fly’s brain processes such visual signals as contour and contrast, it utilizes a kind of detection mechanism which automatically filters out unimportant information, and only pays attention to moving objects liable to collide with.

By imitating this detection mechanism, the research team has developed an AI chip which makes it possible to use hand gestures and an image sensor to operate a drone.

First the drone is taught to focus on what’s most important, and then it’s taught how to judge distance and the likelihood of a collision. For this purpose, Lo conducted a detailed investigation on how the fruit fly detects optical flow, for which purpose he made extensive use of the maps of the fruit fly’s neural pathways produced by the Brain Research Center at NTHU. “Optical flow is the relative trajectory left in the field of vision by nearby moving objects, and which is used by the brain to determine its distance and to avoid obstacles,” Lo explained.

Tang said that the AI chip developed by his research team represents a major breakthrough in the area of in-memory computing. Computers and mobile phones first move data from the memory to the CPU’s central processing unit, and once it’s processed, the data is moved back to the memory for storage, and such a process is what consumes up to 90% of the energy and time of the AI deep-learning process. By contrast, the AI chip developed by the NTHU team mimics neuronal synapses, allowing it to perform computations in the memory, which greatly improves efficiency.

Link:

ClickThru

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye